REDX — Redx Pharma Share Price
Last trade - 00:00- £46.68m
- £46.27m
- £4.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.91 | ||
| Price to Tang. Book | 15.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -730.61% | ||
| Return on Equity | -180.8% | ||
| Operating Margin | -804.85% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 3.13 | 5.68 | 10.04 | 18.69 | 4.2 | 13.73 | 1.25 | 100.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company’s product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohn’s disease.
Directors
- Jane Griffiths NEC (65)
- Lisa Anson CEO (52)
- Peter Collum CFO
- James Mead COO (43)
- Jane Robertson OTH
- Andrew Booth SEC
- Natalie Berner NED
- Thomas Burt NED (41)
- Rob Scott NED
- Bernhard Kirschbaum NID (62)
- Peter Presland NID
- Sarah Wild NID (62)
- Last Annual
- September 30th, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- September 7th, 2010
- Public Since
- March 27th, 2015
- No. of Employees
- 101
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 388,985,916
- Address
- Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG
- Web
- https://www.redxpharma.com/
- Phone
- +44 1625469900
- Auditors
- Ernst & Young LLP
Latest News for REDX
Upcoming Events for REDX
Full Year 2023 Redx Pharma PLC Earnings Release
Half Year 2024 Redx Pharma PLC Earnings Release
Similar to REDX
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in Redx Pharma are trading at 12.00p. This share price information is delayed by 15 minutes.
Shares in Redx Pharma last closed at 12.00p and the price had moved by -61.9% over the past 365 days. In terms of relative price strength the Redx Pharma share price has underperformed the FTSE All Share Index by -61.89% over the past year.
The overall consensus recommendation for Redx Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Redx Pharma does not currently pay a dividend.
Redx Pharma does not currently pay a dividend.
Redx Pharma does not currently pay a dividend.
To buy shares in Redx Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 12.00p, shares in Redx Pharma had a market capitalisation of £46.68m.
Here are the trading details for Redx Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: REDX
Based on an overall assessment of its quality, value and momentum Redx Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Redx Pharma is 130.00p. That is 983.33% above the last closing price of 12.00p.
Analysts covering Redx Pharma currently have a consensus Earnings Per Share (EPS) forecast of -£0.06 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Redx Pharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -57.26%.
As of the last closing price of 12.00p, shares in Redx Pharma were trading -46.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Redx Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 12.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Redx Pharma's management team is headed by:
- Jane Griffiths - NEC
- Lisa Anson - CEO
- Peter Collum - CFO
- James Mead - COO
- Jane Robertson - OTH
- Andrew Booth - SEC
- Natalie Berner - NED
- Thomas Burt - NED
- Rob Scott - NED
- Bernhard Kirschbaum - NID
- Peter Presland - NID
- Sarah Wild - NID